

EGFR MUTATIONS IN NON SMALL CELL LUNG CANCER PATIENTS IN SOUTH AFRICA

Sze Wai Chan

A research report submitted to the Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, in partial fulfillment of the requirements for the degree of Master of Medicine in the branch of Internal Medicine / Medical Oncology.

Johannesburg

1st September 2014

DECLARATION

I, Sze Wai Chan declare that this research report is my own work. It is being submitted for the degree of Master of Medicine in Internal Medicine / Medical Oncology in the University of the Witwatersrand, Johannesburg. It has not been submitted before for any degree or examination at this or any other University.



SZE WAI CHAN

1st Sept. 2014

DATE

DEDICATION

This work is dedicated to my loving parents

ABSTRACT

Introduction: Tyrosine kinase inhibitors and EGFR mutations has changed the treatment approach to lung cancer globally. This retrospective study will look at factors associated with EGFR mutations and define the EGFR mutation rate in South Africa.

Methods: Retrospective record review from NSCLC patients in South Africa who were tested for EGFR mutations at Lancet Laboratories during 1st September 2009 to 30th June 2012. Chi-squared test was used to determine association with categorical variables. Kaplan- Meier survival analysis was done for OS and PFS between EGFR mutation positive and negative patients. Cox proportional hazards were used for subgroup analysis. Treatment practices and response were described.

Results: 170 lung cancer samples were evaluable for EGFR mutation and 37 were EGFR mutation positive (21.8%). There were 22 (59.5%) exon 19 deletions, 11 (29.7%) L858R mutations, two G719X mutations, one S768I mutation and one exon 20 insertion. The median age was 63 (range 27-85). There were more females (55.6%) than males (44.4%) sent for mutation testing. Most patients were whites (71%), followed by blacks (18.3%), and other race (10.7%). 85% of all NSCLC samples tested were adenocarcinoma. None of the squamous cell carcinoma tested was positive for EGFR mutation. Smoking status was inversely proportional to EGFR mutation status ($p < 0.001$). Over 60% patients received chemotherapy first and second line and responses decreased with each line of chemotherapy. Median PFS and OS were not different between the EGFR mutation positive and negative groups (6.85 versus 6.8 months; HR 1.6; 95% CI 0.70-3.65; $p = 0.2543$ and 11.5 versus 12.9 months; HR 0.70;

95% CI 0.28-1.75; $p=0.44$, respectively). On multivariate analysis, only non-white race was associated with decrease in OS (HR 6.66; 95% CI 2.31-19.19; $p=0.0004$).

Conclusion: EGFR mutation rate in South African lung cancer patients was 21.8%.

89% of all EGFR mutations were either exon 19 deletions or L858R point mutations.

Most EGFR mutations were associated with adenocarcinoma of the lung in non-smokers. These findings were consistent with current literature in western countries.

Treatment practice remained chemotherapy based, with few patients receiving EGFR TKIs. Efforts should be made to prioritize targeted treatment approach in lung cancer in South Africa.

ACKNOWLEDGEMENTS

I would like to acknowledge the following people:

1. Professor Paul Ruff for the supervision, encouragement and guidance throughout this project.
2. Dr Chris Maske of the Molecular Division of Lancet Laboratories, for his contribution, advice and patience and for helping me to collect and analyse data for this project.
3. Dr Clem Penny, Wits University for project guidance.
4. Sister Patience Mabaso at the Medical Oncology Clinic, Area 495, Charlotte Maxeke Johannesburg Academic Hospital.
5. Drs Adam and Owen Nosworthy, Dr Georgia Demetriou, Dr Ashraf Wadee and Dr Devan Moodley at the Medical Oncology Unit at the Wits Donald Gordon Medical Centre, for assistance with data collection
6. Dr Bernardo Rapoport of Rosebank Oncology, for his encouragement, advice and readiness to assist with data collection.
7. Dr Daniel Vorobiof and Dr Keorapetse Tabane at Sandton Oncology Centre, for their help with data collection and support.
8. And the following doctors who had help to collect clinical data through telecommunications:
 - a. Dr Samuel Fourie (Wilgers Oncology Centre, Pretoria)
 - b. Dr Gary McMichael and Dr Daleen Geldenhuys (West Rand Oncology Centre)
 - c. Dr Dino Chetty (Wits Donald Gordon Medical Centre)

- d. Dr Sayeuri Buddu (University of Free State, Bloemfontein)
 - e. Dr Elré van Heerden (GVI Oncology, George)
 - f. Dr Leon Gouws (GVI Oncology, Cape Town)
9. Mr Leon Spamer from AstraZeneca for his support and management of the Iressa™ Donation Programme.
10. AstraZeneca provided gefitinib (Iressa™) for South African patients (both state and private sectors) who harboured activating EGFR mutations in non small cell lung cancer free of charge under the Iressa™ Donation Programme. The programme also provided the EGFR mutation tests for the state patients. This in turn had benefited many patients who had activating EGFR mutation positive non-small cell lung cancers.
11. Mrs Sandra Lombaard in Area 495, Charlotte Maxeke Johannesburg Academic Hospital, for her administrative assistance with the patients on the Iressa™ Donation Programme.

TABLE OF CONTENTS

| | Page |
|--|-------------|
| DECLARATION | ii |
| DEDICATION | iii |
| ABSTRACT | iv |
| ACKNOWLEDGEMENTS | vi |
| TABLE OF CONTENTS | viii |
| LIST OF FIGURES | x |
| LIST OF TABLES | xi |
| DEFINITION OF TERMS | xii |
| ABBREVIATIONS | xiii |
| | |
| 1.0 INTRODUCTION | 1 |
| 1.1 Lung cancer – general overview | 1 |
| 1.2 Lung cancer in never smokers – a new entity | 2 |
| 1.3 Epidermal growth factor receptor and signaling pathways | 4 |
| 1.4 EGFR tyrosine kinase inhibitors and EGFR activating mutations | 5 |
| 1.5 Development of TKI and studies before 2004 | 6 |
| 1.6 Discovery of EGFR activating mutations and increase response to TKI | 9 |
| 1.7 Second- / third-line TKI studies versus placebo | 10 |
| 1.8 Second-line studies with TKI versus chemotherapy | 13 |
| 1.9 First-line studies of TKI versus chemotherapy | 17 |
| 1.10 Maintenance therapy | 21 |
| 1.11 Side effects of TKIs | 23 |
| 1.12 Acquired resistance from long term TKI therapy | 23 |
| 1.13 Summary of gefitinib and erlotinib | 24 |
| 1.14 Second generation tyrosine kinase inhibitors | 25 |
| 1.15 EGFR overexpression | 26 |
| 1.16 Other molecular developments in lung cancer | 27 |
| 1.16.1 EML4-ALK translocation | 27 |
| 1.16.2 ALK tyrosine kinase inhibitors | 28 |
| 1.16.3 Molecular diagnosis of ALK rearrangement positive NSCLC | 32 |
| 1.16.4 VEGF inhibition | 33 |
| 1.16.5 cMet overexpression | 34 |
| 1.16.6 Lung Cancer Mutation Consortium | 35 |
| 1.17 Summary and situation in South Africa | 37 |
| | |
| 2.0 PATIENTS AND METHODS | 40 |
| 2.1 Methods of data collection and timeline | 40 |
| 2.2 Descriptive review | 41 |
| 2.3 Statistical analysis and objectives | 42 |
| 2.4 Methods of detecting EGFR mutations | 42 |
| | |
| 3.0 RESULTS | 44 |
| 3.1 EGFR mutation rate | 44 |

| | |
|--|-----------|
| 3.2 Specific EGFR mutations | 44 |
| 3.3 Demographics and clinical characteristics | 46 |
| 3.4 First-line treatments received in NSCLC | 54 |
| 3.5 Response assessment post first-line systemic treatments | 56 |
| 3.6 Second- and third-line treatments in NSCLC | 58 |
| 3.7 Response assessment post second-line systemic treatments | 58 |
| 3.8 Progression free survival | 61 |
| 3.9 Overall Survival | 64 |
| | |
| 4.0 DISCUSSION AND CONCLUSION | 69 |
| 4.1 Comparison to current literature | 69 |
| 4.2 Challenges of lung cancer treatment in South Africa | 70 |
| 4.3 Limitations of this study | 72 |
| 4.4 Future direction | 73 |
| | |
| APPENDIX A DATA COLLECTION TABLE | 74 |
| APPENDIX B Permission from the Molecular Pathology Department of Lancet Laboratories, Johannesburg for the use of EGFR mutation results | 76 |
| APPENDIX C Permission from the Division of Medical Oncology, Charlotte Maxeke Johannesburg Academic Hospital for record review | 77 |
| APPENDIX D Permission from the CEO of Charlotte Maxeke Johannesburg Academic Hospital for record review | 78 |
| APPENDIX E Permission from Wits Donald Gordon Medical Centre for patient's file review | 79 |
| APPENDIX F University of Witwatersrand Human Research Ethics Committee (HREC) (Medical) Approval | 80 |
| APPENDIX G Presentations and abstract from 2011 SASCRO/SASMO Congress | 81 |
| APPENDIX H Letter from Sanofi | 82 |
| | |
| REFERENCES | 83 |

LIST OF FIGURES

| Figure | Page |
|--|-------------|
| 3.1 Racial distribution of patients tested for EGFR mutations | 49 |
| 3.2 NSCLC histology submitted for EGFR mutation testing | 50 |
| 3.3 Smoking status and positive EGFR mutation status | 52 |
| 3.4 Smoking status and negative EGFR mutation status | 53 |
| 3.5 First-line treatments received in NSCLC | 55 |
| 3.6 Second-line treatments received in NSCLC | 59 |
| 3.7 Progression Free Survival in EGFR mutation positive and negative groups | 62 |
| 3.8 Overall survival and EGFR mutation positive and negative groups in NSCLC | 65 |
| 3.9 Overall Survival and Race in the EGFR mutation positive group | 67 |
| 3.10 Overall Survival and Race in EGFR mutation negative group | 68 |

LIST OF TABLES

| Table | Page |
|--|-------------|
| 3.1 Type of EGFR mutations | 45 |
| 3.2 Clinical characteristics in EGFR mutation positive and negative patients | 48 |
| 3.3 Smoking status of all patients who had EGFR mutation testing | 51 |
| 3.4 RECIST 1.0 response assessment post first-line systemic therapy | 57 |
| 3.5 Response assessment post second-line systemic treatments | 60 |
| 3.6 Multivariate analysis of Progression Free Survival | 63 |
| 3.7 Multivariate analysis of Overall Survival | 66 |

DEFINITION OF TERMS

Smoking status was defined according to the IPASS and the Spanish screening study from Rosell et al (21, 23).

NEVER SMOKERS: < 100 lifetime cigarettes

FORMER SMOKERS: \geq 1 year since cessation

CURRENT SMOKERS: Still smoking, or < 1 year since cessation

FORMER LIGHT SMOKERS: stopped smoking at least 15 years previously and had a total of \leq 10 pack-years of smoking

RESPONSE RATE: Measured by Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria (99)

PROGRESSION FREE SURVIVAL (PFS): From the date of first treatment to the earliest sign of disease progression, as determined by means of the RECIST 1.0

OVERALL SURVIVAL (OS): From the date of first treatment until death from any cause

LOST TO FOLLOW UP: Patient did not return for follow up visits AND unable to contact patient by telephonic means in 3 separate consecutive occasions

ABBREVIATIONS

ALK: Anaplastic Lymphoma Kinase

ASR: Age Standardized incidence Rate (per 100,000 population)

DCR: Disease Control Rate

ECOG: Eastern Cooperative Oncology Group

EGFR: Epidermal Growth Factor Receptor

EMA: European Medicines Agency

ESMO: European Society for Medical Oncology

FACT-L: Functional Assessment of Cancer Therapy-Lung (100)

FDA: Food and Drug Administration of USA

HR: Hazard Ratio

IARC: International Agency for Research on Cancer

IHC: Immunohistochemistry

ITT: Intention To Treat

LCINS: Lung Cancer In Never Smokers

LR: Lifetime Risk of developing a cancer before the age of 74 years

NSCLC: Non-Small Cell Lung Cancer

OR: Odds Ratio

OS: Overall Survival

PFS: Progression Free Survival

PM: Particulate Matter

RR / ORR: Response rate / Overall Response Rate

SASCRO: South African Society of Clinical and Radiation Oncology

SASMO: South African Society of Medical Oncology

SEER: Surveillance, Epidemiology, and End Results

TKI: Tyrosine Kinase Inhibitors

TTP: Time To Progression

WHO: World Health Organization